Free Trial

Alnylam Pharmaceuticals (ALNY) Competitors

Alnylam Pharmaceuticals logo
$320.87 +3.37 (+1.06%)
Closing price 07/9/2025 04:00 PM Eastern
Extended Trading
$326.98 +6.11 (+1.90%)
As of 09:08 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ALNY vs. AMGN, GILD, VRTX, REGN, BIIB, INCY, UTHR, NBIX, EXEL, and BMRN

Should you be buying Alnylam Pharmaceuticals stock or one of its competitors? The main competitors of Alnylam Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Incyte (INCY), United Therapeutics (UTHR), Neurocrine Biosciences (NBIX), Exelixis (EXEL), and BioMarin Pharmaceutical (BMRN). These companies are all part of the "biotechnology" industry.

Alnylam Pharmaceuticals vs. Its Competitors

Alnylam Pharmaceuticals (NASDAQ:ALNY) and Amgen (NASDAQ:AMGN) are both large-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, media sentiment, profitability, dividends, earnings, risk and institutional ownership.

Alnylam Pharmaceuticals has a beta of 0.23, indicating that its share price is 77% less volatile than the S&P 500. Comparatively, Amgen has a beta of 0.49, indicating that its share price is 51% less volatile than the S&P 500.

Alnylam Pharmaceuticals currently has a consensus price target of $341.91, suggesting a potential upside of 6.56%. Amgen has a consensus price target of $307.82, suggesting a potential upside of 3.81%. Given Alnylam Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts plainly believe Alnylam Pharmaceuticals is more favorable than Amgen.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Alnylam Pharmaceuticals
1 Sell rating(s)
3 Hold rating(s)
21 Buy rating(s)
0 Strong Buy rating(s)
2.80
Amgen
2 Sell rating(s)
12 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
2.35

In the previous week, Amgen had 32 more articles in the media than Alnylam Pharmaceuticals. MarketBeat recorded 48 mentions for Amgen and 16 mentions for Alnylam Pharmaceuticals. Amgen's average media sentiment score of 1.42 beat Alnylam Pharmaceuticals' score of 0.85 indicating that Amgen is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Alnylam Pharmaceuticals
9 Very Positive mention(s)
1 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Amgen
44 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Amgen has higher revenue and earnings than Alnylam Pharmaceuticals. Alnylam Pharmaceuticals is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alnylam Pharmaceuticals$2.25B18.61-$278.16M-$2.09-153.53
Amgen$33.42B4.77$4.09B$10.9627.05

Amgen has a net margin of 17.39% compared to Alnylam Pharmaceuticals' net margin of -11.49%. Amgen's return on equity of 176.11% beat Alnylam Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Alnylam Pharmaceuticals-11.49% -510.31% -6.48%
Amgen 17.39%176.11%12.39%

93.0% of Alnylam Pharmaceuticals shares are held by institutional investors. Comparatively, 76.5% of Amgen shares are held by institutional investors. 1.5% of Alnylam Pharmaceuticals shares are held by company insiders. Comparatively, 0.8% of Amgen shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Amgen beats Alnylam Pharmaceuticals on 11 of the 17 factors compared between the two stocks.

Get Alnylam Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for ALNY and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALNY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ALNY vs. The Competition

MetricAlnylam PharmaceuticalsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$41.40B$2.90B$5.51B$8.95B
Dividend YieldN/A2.44%5.25%4.04%
P/E Ratio-153.5321.0128.0220.16
Price / Sales18.61257.28417.67174.36
Price / CashN/A41.8337.0657.97
Price / Book617.067.868.145.62
Net Income-$278.16M-$54.96M$3.16B$248.50M
7 Day Performance-3.33%5.27%3.16%4.49%
1 Month Performance6.09%3.78%3.49%7.03%
1 Year Performance24.48%5.85%34.22%21.07%

Alnylam Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ALNY
Alnylam Pharmaceuticals
4.116 of 5 stars
$320.87
+1.1%
$341.91
+6.6%
+26.0%$41.40B$2.25B-153.532,230Positive News
Analyst Forecast
AMGN
Amgen
4.5364 of 5 stars
$279.21
+0.8%
$307.82
+10.2%
-6.1%$150.13B$33.42B25.4828,000Positive News
Analyst Revision
GILD
Gilead Sciences
4.8336 of 5 stars
$110.87
+0.2%
$110.55
-0.3%
+67.1%$137.91B$28.74B23.3417,600Trending News
Analyst Revision
VRTX
Vertex Pharmaceuticals
4.4527 of 5 stars
$445.20
+0.9%
$511.62
+14.9%
-1.4%$114.33B$11.02B-113.576,100Positive News
Analyst Revision
REGN
Regeneron Pharmaceuticals
4.9349 of 5 stars
$525.00
+0.8%
$813.57
+55.0%
-47.6%$56.68B$14.20B13.3711,900Analyst Revision
BIIB
Biogen
4.9272 of 5 stars
$125.59
-0.4%
$188.48
+50.1%
-41.9%$18.40B$9.68B12.407,605Positive News
INCY
Incyte
4.4367 of 5 stars
$68.10
-0.4%
$74.53
+9.4%
+13.2%$13.18B$4.24B212.822,617Insider Trade
UTHR
United Therapeutics
4.9962 of 5 stars
$287.35
+1.1%
$386.15
+34.4%
-6.8%$12.96B$2.88B11.471,305Positive News
Analyst Forecast
NBIX
Neurocrine Biosciences
4.7678 of 5 stars
$125.69
+0.2%
$162.00
+28.9%
-6.8%$12.44B$2.36B42.611,800News Coverage
Positive News
Analyst Forecast
Insider Trade
EXEL
Exelixis
4.7079 of 5 stars
$44.08
+0.9%
$43.56
-1.2%
+99.0%$12.02B$2.17B20.041,147Analyst Forecast
Options Volume
BMRN
BioMarin Pharmaceutical
4.9394 of 5 stars
$54.97
-0.4%
$93.45
+70.0%
-28.1%$10.54B$2.85B20.443,040Positive News

Related Companies and Tools


This page (NASDAQ:ALNY) was last updated on 7/10/2025 by MarketBeat.com Staff
From Our Partners